Yoshiaki Nakamura

Dr Yoshiaki Nakamura trained in Medicine at Osaka University and obtained his PhD from Keio University. His clinical and research interests focus on gastrointestinal cancer, liquid biopsy, precision oncology, and early cancer detection. He has led multiple nationwide studies, including SCRUM-Japan and CIRCULATE-Japan, pioneering the clinical use of circulating tumour DNA (ctDNA) for precision medicine and minimal residual disease (MRD) monitoring. Dr Nakamura has served as Principal Investigator on numerous clinical and translational trials that contributed to new drug and companion diagnostic approvals in Japan. 

Dr Nakamura’s research focuses on translating liquid biopsy technologies into clinical practice for precision oncology and early cancer detection. His work integrates circulating tumour DNA (ctDNA) analysis for minimal residual disease (MRD) and multi-cancer early detection (MCED) with artificial intelligence-driven histopathological and genomic modelling. Dr Nakamura aims to build large-scale, data-driven frameworks that bridge clinical trials, molecular profiling, and digital health innovation.